Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
From January 1, 2024, the EC Decision Reliance Procedure (ECDRP) has been replaced by the new international recognition procedure (IRP) that allows fast approval of products that have already received authorization for the same product from one of the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)’s specified Reference Regulators (RRs):Australia, Canada, Switzerland, Singapore, Japan, United States, and European Union. The first product approved is Xgeva/Prolia (denosumab), which has also received biosimilar approvals in the US.
To qualify for IRP submission, the product must have the same qualitative and quantitative composition (active substance(s) and excipients) and the same pharmaceutical form from applicants belonging to the same company or group of companies or ‘licensees.’
IRP can be used for chemical and biological active substances, generic applications, hybrid applications, biosimilar applications, and new fixed combination product applications. IRPs can also be used for post-authorization procedures, including line extensions, variations, and renewals.
There are 2 recognition timetables for initial marketing authorization applications:
The MHRA has always been highly supportive of the entry of biosimilars, but its actions came into place after the United Kingdom got out of the European Union. The MHRA was the first regulatory agency to remove clinical efficacy testing of biosimilars with the following statement:
“Although each biosimilar development needs to be evaluated on a case-by-case basis, it is considered that, in most cases, a comparative efficacy trial may not be necessary if sound scientific rationale supports this approach. Therefore, a well-argued justification for the absence of an efficacy trial should be appended to CTD Module 1 of the submitted application”.
Now, it is possible for biosimilars approved in the qualified regions to be automatically available in the United Kingdom or any other country that may decide to follow these guidelines. This action also removes many misconceptions about biosimilars, such as the need to bridge studies when the reference product is not specific to the country of origin or even conducting comparative efficacy testing. This is an opportunity for all countries listed in the IRP list to adopt the same system of qualifying the registration of biosimilars. Moreover, it is an opportunity for all developing countries to adopt this policy, as I suggested in forming a Global Regulatory Agency that is now under consideration by the United Nations.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.